alexa
Reach Us +1-947-333-4405

GET THE APP

Breast Cancer Subtypes Overview With Emphasis On Racial Disparities | 16403
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google scholar citation report
Citations : 1174

Journal of Clinical & Experimental Pathology received 1174 citations as per google scholar report

Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • Ulrich's Periodicals Directory
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Breast cancer subtypes overview with emphasis on racial disparities

3rd International Conference and Exhibition on Pathology

Gabriela Oprea-Ilies and Momin T. Siddiqui

ScientificTracks Abstracts: J Clin Exp Pathol

DOI: 10.4172/2161-0681.S1.012

Abstract
Breast cancer remains a common cancer diagnosed in women. Its treatment is currently determined by expression of predictive and prognostic markers ER, PR and HER2. More than 50% of breast cancer are ER+/PR+/HER2- and have the best prognosis, due to effective targeted hormonal therapies and a more indolent clinical course. The two HER2+ subtypes represent approximately 20% of breast cancer and prior to targeted therapy, had some of the worst prognosis. The TNT (triple negative tumor) defined as ER/PR/HER2 negative, comprise 10-30% of breast cancers. It has recently emerged as a highly aggressive subtype arising in younger women, prevalent among some ethnic groups (African-American (AA) and Hispanics) and with no available effective targeted therapy using unsupervised gene clustering TNTs may be further subcalssified (basal- like, claudin low, p53 mutated BRCA1 associated etc.), mirroring the different histopathologic appearance, with a range of prognoses and responses to treatment. At molecular levels they show differential expression, by race, of basal cytokeratin, stem cells markers, claudins, growth factors and proliferative genes. In AA women these tumors show signs of aggressivity: clinically are larger at presentation and have a poor outcome; at molecular level they show higher proliferation activity and p53 expression. The high prevalence of TNT, with their accompanying poor survival and unique protein expression patterns, among younger women and particularly younger AA women suggests varying differences in gene-environment. This difference between the TNTs in different ethnic groups is of interest in view of their different biologic behaviors, indicating the need for personalized therapy.
Biography
Gabriela Oprea-Ilies has a medical degree from The Institute of Medicine and Pharmacy, Bucharest, Romania. She completed pathology residency at the University of Minnesota, Twin Cities and Cytology fellowship at Emory University, Atlanta, GA. She studied breast cancer with Dr. Schnitt, Collins and Mallory, in Boston. Currently she is a Pathologist, Assistant Professor and Principal Investigator of the breast tissue bank at Emory University, Director of the Immunolab at Grady Memorial Hospital and Adjunct Professor at Georgia State University. She has published in reputed journals, has been reviewing papers and serving in the editorial board member of repute.
Top